5 results about "Milbemycin oxime" patented technology

The invention provides a preparation method of milbemycin oxime A4, which comprises the following steps: under an acidic condition, carrying out hydrolysis disaccharide removal reaction on tenvermectin B to obtain tenvermectin B aglycone; the preparation method comprises the following steps: carrying out silicon-based protection on tenvermectin B aglycone by adopting a silicon-based protection reagent to obtain 5-hydroxyl silicon-based tenvermectin B aglycone; the preparation method comprises the following steps: brominating 5-hydroxyl silicon-based tenvermectin B aglycone by adopting a brominating reagent to obtain 13-bromine-5-hydroxyl silicon-based protected tenvermectin B aglycone; the preparation method comprises the following steps: reducing 13-bromo-5-hydroxyl silicon group protected tenvermectin B aglycone by using a reducing agent to obtain 5-hydroxyl silicon group protected milbemycins A4; the milbemycins A4 protected by the 5-hydroxyl silicon group is subjected to desilicication protection treatment, and the milbemycins A4 is obtained; oxidizing milbemycins A4 by adopting an oxidizing agent to obtain 5-ketomilbemycins A4; the preparation method comprises the following steps: reacting 5-ketomilbemycins A4 with hydroxylamine hydrochloride to obtain milbemycins A4, and efficiently preparing the active component milbemycins A4 single component by taking tenvermectin B as a raw material.

The present application provides a milbemycin oxime praziquantel-based parasitic expelling drug, which comprises the following components in parts by mass: modified milbemycin oxime 10-30 parts, nano-coated praziquantel 20-50 parts, compound synergist 5-15 parts, flavoring agent 3-8 parts, and disintegrating agent 2-5 parts. The application of the milbemycin oxime praziquantel-based parasitic expelling drug is used for preparing a preparation for preventing or treating mixed parasitic infection of dogs and cats, wherein the parasites include tapeworms, nematodes, trematodes and Demodex. Through the integrated innovation of chemical modification (succinylated milbemycin oxime), nanotechnology (HPMC-coated praziquantel) and compound synergy (non-ban Tai'er-beta cyclodextrin), the comprehensive advantages of broad-spectrum parasitic expelling, long-acting stability, safety and low toxicity are realized, and the pain points such as poor palatability, high metabolic burden and weak environmental adaptability in the prior art are solved, and the application is suitable for the prevention and treatment of mixed parasitic infection of dogs and cats.

The invention relates to the technical field of veterinary preparations, and particularly discloses a compound parasite expelling preparation and a preparation method thereof. The compound parasite expelling preparation provided by the invention is prepared from the following raw material components in parts by mass: 3 to 20 parts of fluralan, 0.3 to 3 parts of milbemycin oxime, 3 to 20 parts of dimethylacetamide, 1 to 6 parts of azone, 1.5 to 10 parts of oleic acid, 3 to 20 parts of propylene glycol and 20 parts of absolute ethyl alcohol. By optimizing the formula and proportioning relation of the preparation, the problems of poor stability and low drug synergistic release efficiency of the existing compound parasite expelling preparation are solved, and the stability and in-vitro release performance of the preparation are obviously improved.

A veterinary extruded soft chew has as active pharmaceutical ingredients (APIs), milbemycin oxime or one of its salts, and praziquantel or one of its salts. The APIs are uniformly dispersed in a matrix having one or more fillers, a polyethylene glycol (PEG), a non-animal based palatant, a disintegrant, a humectant, an oil, water, and preservatives. Neither the milbemycin oxime or one of its salts, nor the praziquantel or one of its salts is coated, granulated or physically separated from the other APIs within the matrix. More importantly, the soft chew does not comprise any palatant of animal origin.

A veterinary extruded soft chew has as active pharmaceutical ingredients (APIs), milbemycin oxime or one of its salts, and praziquantel or one of its salts. The APIs are uniformly dispersed in a matrix having one or more fillers, a polyethylene glycol (PEG), a non-animal based palatant, a disintegrant, a humectant, an oil, water, and preservatives. Neither the milbemycin oxime or one of its salts, nor the praziquantel or one of its salts is coated, granulated or physically separated from the other APIs within the matrix. More importantly, the soft chew does not comprise any palatant of animal origin.